Department of Psychology, University of Nebraska-Lincoln, Lincoln, NE, USA.
Psychopharmacology (Berl). 2022 Mar;239(3):819-830. doi: 10.1007/s00213-022-06072-1. Epub 2022 Feb 9.
Bupropion is a non-nicotine medication for smoking cessation that has overlapping stimulus effects with nicotine as demonstrated in drug discrimination studies. Whether these shared stimulus effects will alter acquisition or maintenance of a discrimination between nicotine and bupropion is unknown.
We sought to test this possibility using the drug discriminated goal-tracking (DGT) task and whether discrimination training history affected generalization and substitution tests.
Sixty adult Sprague-Dawley rats (30M/30F) were equally split into three discrimination training groups: SAL-0.4NIC, 10BUP-0.4NIC, and 20BUP-0.4NIC. On nicotine days, all rats were administered subcutaneously 0.4 mg/kg nicotine and had intermittent access to liquid sucrose. On intermixed non-reinforced days, rats were administered intraperitoneally saline, 10 or 20 mg/kg bupropion. Upon completion, a range of nicotine and bupropion doses were assessed before substitution tests with varenicline and sazetidine-A were conducted.
The SAL-0.4NIC and 10BUP-0.4NIC groups readily discriminated by session 8, as evidenced by increased dipper entries (goal-tracking) on nicotine days. The 20BUP-0.4NIC group was slower to acquire the discrimination. Female rats, regardless of group, had higher conditioned responding evoked by the lowest dose of nicotine (0.025 mg/kg) in the dose-effect curve. The discrimination required rats to learn to withhold responding to the training dose of bupropion. This withholding of excitatory dipper entries generalized to other doses. Varenicline and sazetidine-A partially substituted for the nicotine stimulus, and this pattern did not differ with training history.
We are the first to study a drug-drug discrimination using the DGT task. Females appeared to have a lower discrimination threshold for nicotine that was not impacted by the learning history. Further work on the importance of sex as a biological variable and how the complex interoceptive stimulus effects of nicotine can vary with training histories is needed.
安非他酮是一种非尼古丁戒烟药物,在药物辨别研究中显示出与尼古丁重叠的刺激作用。这些共同的刺激作用是否会改变尼古丁和安非他酮之间辨别关系的获得或维持尚不清楚。
我们试图使用药物辨别目标跟踪(DGT)任务来测试这种可能性,以及辨别训练史是否会影响泛化和替代测试。
60 只成年 Sprague-Dawley 大鼠(30M/30F)平均分为三组辨别训练组:SAL-0.4NIC、10BUP-0.4NIC 和 20BUP-0.4NIC。在尼古丁日,所有大鼠均接受皮下注射 0.4mg/kg 尼古丁,并间歇性地摄入液体蔗糖。在混合无强化日,大鼠接受腹腔注射生理盐水、10 或 20mg/kg 安非他酮。完成后,在进行瓦伦西丁和沙唑替丁-A 的替代测试之前,评估了一系列尼古丁和安非他酮剂量。
SAL-0.4NIC 和 10BUP-0.4NIC 组在第 8 次试验时就能轻易辨别,这表现在尼古丁日时,勺形进入(目标跟踪)的增加。20BUP-0.4NIC 组则较慢地获得辨别。无论组如何,雌性大鼠在剂量反应曲线上对最低剂量的尼古丁(0.025mg/kg)表现出更高的条件反应。辨别要求大鼠学会抑制对训练剂量的安非他酮的反应。这种抑制兴奋勺形进入的行为泛化到其他剂量。瓦伦西丁和沙唑替丁-A 部分替代了尼古丁刺激,而且这种模式与训练史无关。
我们首次使用 DGT 任务研究药物-药物辨别。女性似乎对尼古丁的辨别阈值较低,而训练史并不影响这一阈值。需要进一步研究性别作为生物学变量的重要性,以及尼古丁复杂的内感受性刺激作用如何随训练史而变化。